Dry Eye
539
41
50
361
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Published Results
130 trials with published results (24%)
Research Maturity
361 completed trials (67% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
4.1%
22 terminated out of 539 trials
94.3%
+7.7% vs benchmark
27%
146 trials in Phase 3/4
36%
130 of 361 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 361 completed trials
Clinical Trials (539)
Effect of Acoltremon Ophthalmic Solution 0.003% on Tear Production and Symptoms in Patients With Tear Deficiency and Concurrent Neuropathic Corneal Pain
Comparing Efficacy of Tea Tree Oil Versus Topical Azithromycin in Treating Dry Eye
Contact Lens-Wearing Dry Eye Subjects Who Are Treated With Acoltremon 0.003%
A Study to Evaluate the Performance and Safety of Artelac® Complete MDO® Versus VISMED® MULTI Eye Drops in the Management of Moderate to Severe Dry Eye Disease
Switching From Preserved Glaucoma Therapy to Preservative-Free ZOLYMBUS
Ocular Surface Disease in Glaucoma Patients on Long-Term Therapy
Preliminary Clinical Study of the Effectiveness and Safety of Ocular Surface Microbiota Transplantation in the Treatment of Dry Eye Disease
Evaluation of Lacrifill
Dry Eye Screening and Referral System
A Study of Full-Spectrum Screen Lighting for Reducing Screen-Related Eye Fatigue and Dry Eye
Yogic Eye Exercises for Computer Vision Syndrome in Female Design Students
Proteomics Analysis of Human Tears in the Diagnosis and Management of Dry Eye Disease
Temporary Tear Duct Filling With Hyaluronic Acid Gel and Assessment of Dry Eye Disease (DED) After Bilateral Cataract Surgery
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3
BL-RX01-TFSTAB-1402
Comparing Efficacy of Autologous Serum Eye Drops With and Without Insulin in Autoimmune Dry Eye.
Long-term Effects of Acoltremon vs. Control in Dry Eye Disease
Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease
Topical Insulin for Ocular Surface Interface in Dry Eye Disease
Phase III Study of OT202 in Treating Moderate to Severe Dry Eye